The neuromuscular junction has retained through evolution the capacity to regenerate after damage, but little is known on the inter-cellular signals involved in its functional recovery from trauma, autoimmune attacks, or neurotoxins. We report here that CXCL12a, also abbreviated as stromal-derived factor-1 (SDF-1), is produced specifically by perisynaptic Schwann cells following motor axon terminal degeneration induced by a-latrotoxin. CXCL12a acts via binding to the neuronal CXCR4 receptor. A CXCL12a-neutralizing antibody or a specific CXCR4 inhibitor strongly delays recovery from motor neuron degeneration in vivo. Recombinant CXCL12a in vivo accelerates neurotransmission rescue upon damage and very effectively stimulates the axon growth of spinal cord motor neurons in vitro. These findings indicate that the CXCL12a-CXCR4 axis plays an important role in the regeneration of the neuromuscular junction after motor axon injury. The present results have important implications in the effort to find therapeutics and protocols to improve recovery of function after different forms of motor axon terminal damage.
Introduction
The neuromuscular junction (NMJ) is a specialized tripartite synapse formed by the motor axon terminal (MAT) and the muscle fiber (MF), which are separated by a basal lamina (BL), and covered by perisynaptic Schwann cells (PSCs). This is the best-studied synapse, and most of what is presently known about development, structure, and function of a synapse derives from studies on the NMJ. The NMJ is not protected by anatomical barriers, and it is subjected to traumas and to the attack of many pathogens, including neurotoxins and autoimmune antibodies. For these reasons and for its essential role in life and survival, the NMJ, unlike the central nervous system synapses, has retained throughout vertebrate evolution the capacity to regenerate (Brosius Lutz & Barres, 2014) . Damaged MATs regenerate readily forming new NMJs that look and perform as the original ones (Son et al, 1996; Sanes & Lichtman, 1999; Darabid et al, 2014) . Hence, the NMJ is a privileged system to study the inter-and intracellular signaling occurring during MAT degeneration and, more importantly, of those governing the ensuing regeneration.
We have recently established a murine model of NMJ degeneration and regeneration based on the specific and acute actions of a-latrotoxin (a-LTx) or of snake presynaptic PLA 2 neurotoxins (Dixon & Harris, 1999; Rigoni et al, 2004 Rigoni et al, , 2005 Ushkaryov et al, 2008) , with the aim of identifying the molecules involved in intraand inter-cellular signaling governing NMJ regeneration (Duregotti et al, 2015; Rigoni & Montecucco, 2017) . These neurotoxins bind specifically to the presynaptic membrane and induce a large Ca 2+ entry into nerve terminals, with exocytosis of synaptic vesicles, rounding and degeneration of mitochondria, and Ca 2+ -induced activation of hydrolases such as calpains (Rigoni et al, 2007 (Rigoni et al, , 2008 Tedesco et al, 2009; Duregotti et al, 2013) . This causes the complete MAT degeneration with formation of debris that are phagocytosed by PSCs, without recruitment of inflammatory cells. PSCs become activated during MAT degeneration by signals which include mitochondrial and cytosolic alarmins (Duregotti et al, 2015; Negro et al, 2016) . PSCs play an essential role in regeneration, not limited to the clearing of necrotic debris (Son et al, 1996; Sanes & Lichtman, 1999; Jessen et al, 2015) . Stimulated PSCs, together with MF, are believed to produce and release a series of factors that act on the motor axon stump inducing its growth until contacts with the BL are re-established, with resumption of regulated neurotransmitter release (Son et al, 1996; Sanes & Lichtman, 1999; Darabid et al, 2014) .
In mice, the entire degeneration and regeneration process induced by a-LTx is completed within about 5 days with no apparent inflammatory response, thus making the task of identifying inter-cellular signals simpler. We carried out a transcriptome analysis of the NMJ at different time points after injection of a-LTx, to identify novel intra-and inter-cellular signaling molecules. Among the many messenger RNAs (mRNAs) differentially expressed during degeneration and regeneration, we investigated the role of the chemokine CXCL12a (also abbreviated as stromalderived factor 1, SDF-1). Here, we provide compelling evidence that CXCL12a is produced by activated PSCs and plays an important role in NMJ regeneration by inducing the growth of the motor axon.
Results

CXCL12a mRNA increases during NMJ degeneration
To determine the transcriptome program of murine NMJs during acute degeneration of MAT followed by complete regeneration, we used an animal model that we recently developed (Duregotti et al, 2015) . The time course of a-LTx-induced reversible degeneration was defined by staining over time the presynaptic markers SNAP25 (synaptosomal-associated protein 25) and VAMP1/synaptobrevin. We employed transgenic mice expressing a cytosolic GFP in Schwann cells (SCs) under the plp promoter (Mallon et al, 2002) to visualize PSCs. In Levator auris longus (LAL) muscles (Angaut-Petit et al, 1987) injected with a-LTx, there is a progressive fragmentation of presynaptic nerve terminals that peaks at 4 h; with time, a gradual reappearance of SNAP25 ( Fig 1A) and VAMP1 ( Fig 1B) takes place, with the motor axon end plate returning similar to controls by 96 h. Therefore, we performed a transcriptome analysis of NMJs from LAL, a muscle very suitable for NMJs collection by laser microdissection, from samples taken at 4, 24, 96 h after a-LTx injection. Total RNA was extracted, quality-controlled, retro-transcribed, amplified, and sequenced ( Fig EV1) , and results were compared with those of controls.
Among the mRNAs differentially expressed during MAT degeneration and regeneration, we focused on the one encoding for CXCL12a, which is poorly expressed in controls, upregulated at 4 h (MAT degenerated and active phagocytosis of debris by PSCs), and returns to low expression later on ( Fig 1C) . Such pattern of CXCL12a mRNA change with time was confirmed also in soleus muscle by droplet digital PCR (Figs 1D and EV2) .
CXCL12a was previously reported to play an active role in neuronal development (Lieberam et al, 2005; Arnò et al, 2014; Shellard & Mayor, 2016) . Given that development and regeneration may share molecules and signaling pathways, we tested the possibility that CXCL12a plays a role in the regrowth of the motor axon stump to reform a functional NMJ.
CXCL12a is expressed by PSCs during NMJ degeneration
The sampling protocol developed here provides RNA from MAT, PSCs, and MF at the same time; therefore, RNA transcripts cannot be directly attributed to one cell type. To identify the cellular origin of CXCL12a, we performed at the NMJ both fluorescence in situ hybridization (FISH) and immunohistochemistry. CXCL12a mRNA signal is barely detectable in control NMJs, but becomes evident 4 h post-injection within PSCs (Fig 1E) . Using a specific antibody, we found that CXCL12a is contained inside PSCs granules (56 AE 5% of CXCL12a-positive NMJs; Fig 1F, arrows and orthogonal projection). In agreement with the transcriptomic profile, the intensity of CXCL12a staining decreases with time, becoming practically absent at 96 h, when regeneration is well under way. These data indicate that the production of this chemokine by PSCs is an early event.
Neutralization of CXCL12a delays NMJ regeneration in vivo CXCL12 knockout mice are not viable (Nagasawa et al, 1996) , and in conditional CXCL12a knockout mice protein disappearance is incomplete (Arnò et al, 2014) . To assess whether CXCL12a plays a role in the regeneration of damaged NMJs, we followed the classical approach used for nerve growth factor (Angeletti et al, 1971) . We injected intraperitoneally a CXCL12a-neutralizing IgG monoclonal antibody before a-LTx injection in the mice hind limb. By this approach, the biochemical knockout of the chemokine begins rapidly after antibody injection and lasts for a long time, as the halflife of murine IgG antibodies exceeds 11 days (Sigounas et al, 1994) . Recovery of muscle contraction was measured by recording the evoked junctional potentials: NMJ regain of function is significantly delayed at 72 and 96 h in the presence of the anti-chemokine antibody (Fig 2A) , in line with its slower anatomical recovery, as assessed by immunostaining the presynaptic marker VAMP1 ( Fig EV3) . Injection of the sole anti-chemokine antibodies has no effect on neurotransmission. As expected, the impairment of regeneration is not complete, given that the process is driven and governed by a set of factors (Sanes & Lichtman, 1999; Darabid et al, 2014) . In this light, the effect of CXCL12a on nerve recovery of function is even more remarkable.
CXCL12a promotes axonal growth in cultured spinal cord motor neurons
In cultured cerebellar and hippocampal neurons, CXCL12a was shown to promote axonal elongation (Arakawa et al, 2003; Pujol et al, 2005) . Accordingly, we tested the effect of recombinant CXCL12a (rCXCL12a) on primary cultures of spinal cord motor neurons (SCMNs) grown in culture dishes (Arce et al, 1999) . Figure 2B shows that rCXCL12a (500 ng/ml) strongly stimulates axon elongation, and panel C provides a quantitative estimation of this effect. This concentration was used before (Opatz et al, 2009; Heskamp et al, 2013) , and it appears appropriate if one considers that the chemokine is released from PSCs into the very small volume between nerve terminals and PSCs. The growth-promoting effect of CXCL12a can be better appreciated in microfluidic devices, which consist of a somatic chamber, where neurons are plated, connected to a distal chamber, containing the chemokine, In these microfluidic plates, the stimulus is applied directionally as a gradient from the distal chamber versus the axon tip. An additional advantage of these devices is that one can measure number and length of single axons growing within the groove. rCXCL12a failed to promote axonal elongation when applied to the somatic chamber, suggesting that it acts by interacting with axonal receptors ( Fig EV4) .
Remarkably, local administrations of rCXCL12a after neurotoxin injection in the mice soleus muscle accelerated the functional recovery of degenerated nerve terminals, as assessed by electrophysiological recordings ( Fig 2G) .
The CXCL12a-CXCR4 axis directs motor axon growth in vivo and in vitro
In the immune and nervous systems, CXCL12a signals mainly via the CXCR4 receptor (Chalasani et al, 2003; Lieberam et al, 2005; Pujol et al, 2005; Guyon, 2012; Nagasawa, 2014) . This receptor is well expressed in cultured SCMNs: it concentrates at the growing tips of axons ( Fig 3A, arrow) , similar to what found in isolated brain neurons in vitro (Arakawa et al, 2003; Pujol et al, 2005) , and colocalizes with the typical growth cone-associated marker GAP43 ( Fig 3B) .
In the adult NMJs, CXCR4 signal is almost undetectable, but becomes evident in the motor axon stump upon a-LTx-induced degeneration ( Fig 3C) , reminiscent of the transient expression of CXCR4 in developing spinal cord neurons (Lieberam et al, 2005) . No CXCR4 was detected by antibody staining in PSCs, nor it was revealed by our NMJ transcriptome analysis, which does not include mRNAs from neuronal cell bodies.
AMD3100 is a specific CXCR4 antagonist (De Clercq et al, 1992; Donzella et al, 1998) . When AMD3100 was applied to the somatic chamber of microfluidic devices, the promotion of axon growth exerted by rCXCL12a was reduced ( Fig 3D and E) . The same result was obtained with SCMNs grown in culture dishes ( Fig EV5) .
AMD3100, administered intraperitoneally in mice, delays NMJ recovery from paralysis caused by a local injection of a-LTx in the hind limb, monitored by electrophysiology ( Fig 3F) . This result provides a pharmacological evidence of the involvement of a functional CXCL12a-CXCR4 axis in NMJ regeneration in vivo.
The CXCL12a-CXCR4 axis is modulated by the atypical chemokine receptor 3 (ACKR3; Cruz-Orengo et al, 2011; Bachelerie et al, 2013) , which acts as a scavenger for the chemokine (Naumann et al, 2010; Abe et al, 2014) . However, we did not detect ACKR3 on nerve terminals of LAL muscle in transgenic mice expressing the GFP-ACKR3 construct (Cruz-Orengo et al, 2011; not shown).
Altogether, these findings indicate that the CXCL12a-CXCR4 axis operates in MAT recovery of function after an acute degeneration, supporting the view that NMJ regeneration recapitulates at least some of the events underpinning its development (Sanes & Lichtman, 1999; Darabid et al, 2014) .
Discussion
The major findings of the present paper are as follows: (i) CXCL12a is produced at the adult NMJ by PSCs activated by signals from injured motor axon terminals; (ii) this chemokine plays a relevant role in the process of NMJ regeneration in vivo by interacting with the receptor CXCR4 expressed on the motor neuron stump. These results have a double value: a translational one, as rCXCL12a could be included in a mixture of factors to be used to regenerate damaged NMJs, and a basic science indication that MAT regeneration recapitulates, at least in part, motor neuron development.
These results were obtained with an acute model of MAT degeneration and regeneration, which is highly reproducible and has a well-defined time course. Moreover, there appears to be little, if any, inflammation, differently from the "classical" cut and/or crush models (Rigoni & Montecucco, 2017) . This model is therefore not blurred by inflammatory mediators in the search of signals exchanged among the partners of the NMJ, thus allowing one to identify immune signals possibly involved in the nervous system, as it is the case of the present work.
We have defined the time course of a-LTx-induced MAT degeneration and regeneration by immunostaining the NMJs of LAL, a very thin mice muscle composed of few fiber layers (Angaut-Petit et al, 1987), very suitable for imaging and collection of NMJs by laser microdissection, and by immunostaining and electrophysiology of the soleus muscle. Four time points were selected to determine the mRNA profile of mice NMJs during degeneration and subsequent recovery by transcriptomics.
We found that CXCL12a mRNA is upregulated during MAT degeneration and then returns to basal levels when regeneration is ◀ Figure 1 . CXCL12a is expressed by perisynaptic Schwann cells during nerve terminal degeneration.
A, B The time course of motor axon terminal degeneration and regeneration induced by a-LTx at LAL NMJs was determined in mice with GFP-expressing SCs (green), using the presynaptic markers SNAP25 (red) (A) and VAMP1 (red) (B); at 4 h, SNAP25 and VAMP1 are phagocytosed inside PSCs. Muscles were fixed 0, 4, 24, and 96 h post-injection. A, B CXCR4 (red) is expressed by primary SCMNs (b 3 -tubulin positive, green) and accumulates in growing tips (arrows). Panel (B) shows CXCR4 co-localization with the growth-cone marker GAP43 (green). Scale bars: 10 lm. C CXCR4 (white) is almost undetectable in control NMJs from LAL muscles, and it becomes evident in nerve terminals (SNAP25-NF positive, red) poisoned by a-LTx (16-h intoxication). GFP-expressing SCs are in green. Scale bars: 10 lm. D, E AMD3100 reduces the axon elongation stimulating ability of rCXCL12a on SCMNs in microfluidic chambers. Axon growth was measured after 5 days of treatment.
Scale bars: 10 lm. Quantification is shown in (E). Each bar represents mean AE SD from six different experiments, 70 neurons measured per experiment. ****P < 0.0001 by ANOVA followed by post hoc Tukey test. F Intraperitoneal administration of the CXCR4 antagonist AMD3100 delays the functional recovery of mice NMJs exposed to a-LTx. Each bar represents mean AE SEM from six animals, 15 EJPs measured per animal. **P = 0.0057 by Student's t-test, unpaired, two-sided. (Sanes & Lichtman, 1999; Darabid et al, 2014) , but also during regeneration in adulthood.
In the present work, the role of CXCL12a has been first tested in vivo, and a clear delay in regeneration was found when the chemokine was neutralized by a specific antibody. This result is remarkable if one considers that nerve regeneration is driven and assisted by an array of factors (Sanes & Lichtman, 1999; Darabid et al, 2014) , and we neutralized only one of them by a single dose of a monoclonal antibody delivered systemically. This in vivo action of CXCL12a is most likely exerted via an elongation promotion effect on the motor axon, as suggested by experiments performed in vitro in neurons grown in microfluidic devices, where axon growth can be visualized and quantified. In addition, local administration of the recombinant chemokine accelerates NMJ functional recovery, in support of its promising therapeutic value.
CXCL12a signals via the receptor CXCR4, as suggested by the inhibitory activity in vivo of growth of the motor axon stump after MAT degeneration exerted by the CXCR4-specific antagonist AMD3100. This result is fully consistent with the effect of the anti-CXCL12a antibody: both agents delayed significantly the recovery of the paralyzed NMJs. Noteworthy, CXCR4 was detected by immunostaining at the tip of growing axons, and AMD3100 reduced the axon growth-stimulating activity of the chemokine. CXCR4 expression becomes detectable in vivo upon a-LTx-induced degeneration, supporting the involvement of this axis in axon regrowth. The absence of CXCR4 in vivo in PSCs excludes the possibility that CXCL12a has an autocrine effect, in agreement with the previous finding that in vitro the chemokine induces the death of primary SCs (Küry et al, 2003) . In addition, the in vitro promotion of axonal growth by CXCL12a and the expression of CXCR4 in SCMNs indicate that primary neuronal cultures are an in vitro model of regeneration more than of development. As such, they appear an appropriate counterpart of the in vivo experiments based on antibodies and specific inhibitors reported here.
CXCL12 was discovered following a screening for proteins endowed with a secretion signal sequence (Tashiro et al, 1993) , and soon after as a stroma-derived factor capable of stimulating the growth of the pre-B-cell population within the bone marrow, and termed therefore stromal cell-derived factor 1 (SDF-1; Nagasawa et al, 1994) . Three variants of CXCL12 have been identified in mice: a, b, and c. The latter isoform is resident in the nucleus, while the beta isoform is expressed by endothelial cells and appears to play a major role in leukocytes recruitment. CXCL12a is involved in the development of various regions of the central nervous system (Bagri et al, 2002; Chalasani et al, 2003; Lieberam et al, 2005) , and the CXCL12-CXCR4 axis regulates a variety of responses in the immune and nervous systems (Lu et al, 2002; Stumm et al, 2003; Lieberam et al, 2005; Zhu et al, 2009; Guyon, 2012) .
In the present work, CXCL12a was found to be produced by PSCs at the NMJs, using a combined mRNA and protein analysis. This is the first evidence for an important and defined role of CXCL12a in the regeneration of the NMJ after MAT damage, and in the axon growth of SCMNs in culture. These results might have translational applications in the formulation of a mixture of growth factors to improve the functional recovery of the NMJ after various types of damage, including genetic neurodegenerative syndromes, and in spinal cord diseases characterized by motor neuron loss.
Materials and Methods
Antibodies and toxins
The following primary antibodies were employed: anti-SNAP25 (mouse monoclonal, SMI81, mouse monoclonal, Covance, catalogue 836301, 1:200), anti-VAMP1 (rabbit polyclonal, 1:200, Rossetto et al, 1996) , anti-CXCL12a (mouse monoclonal, R&D, catalogue mab350, 1:50), anti-b 3 -tubulin (rabbit polyclonal, Synaptic System, catalogue SYSY 302302, 1:200), anti-CXCR4 (rabbit polyclonal, Abcam, catalogue ab7199, 1:50-500), anti-GAP43 (rabbit monoclonal, Abcam, catalogue ab75810, 1:200), anti-neurofilaments (NF) 200 (mouse monoclonal, Sigma, catalogue N0142, 1:200), a-bungarotoxin (a-BTx, Life Technologies, catalogue B35451, 1:200). Secondary antibodies Alexa-conjugated (1:200) were from Life Technologies.
Purified a-LTx was purchased by Alomone (catalogue LSP-130). The purity of the toxin was checked by SDS-PAGE and its neurotoxicity by ex vivo mouse nerve-hemidiaphragm preparations as previously described (Rigoni et al, 2005) . Unless otherwise stated, all reagents were purchased from Sigma.
Ethical statement
C57BL/6 mice expressing cytosolic GFP under the plp promoter (Mallon et al, 2002) were kindly provided by Dr. W.B. Macklin (Aurora, Colorado) with the help of Dr. T. Misgeld (Munchen, Germany). All experimental procedures involving animals and their care were carried out in accordance with National laws and policies (D.L. n. 26, March 14, 2014) and with the guidelines established by the European Community Council Directive (2010/63/UE) and were approved by the local authority veterinary services.
Sample preparation for laser microdissection
Upon isoflurane anesthetization, 2-month-old transgenic C57BL/6 female mice of around 20-25 g were locally injected with a-LTx close to the LAL muscles. Animals were randomized in the experimental groups based on their body weight. The toxin (5 lg/kg) was diluted in 15 ll of physiological saline (0.9% w/v NaCl in distilled water). Control animals were injected with saline. At different time points (0, 4, 24, and 96 h), treated mice were sacrificed by anesthetic overdose followed by cervical dislocation and LAL muscles were immediately fixed with a local injection of 4% PFA for 10 min. Muscles were collected, incubated with fluorescent a-BTx in sterile PBS for 30 min at 37°C, and then frozen in liquid nitrogen. Cryosections (7 lm thick) were transferred to UV-treated microscope glass slides. Microdissection was performed under direct microscopic visualization with PALM RoboMover automatic laser microdissector (Carl Zeiss, Oberkochen, Germany).
RNA isolation
Total RNA was isolated from the microdissected samples by incubation with 50 ll of lysis buffer PKD (Qiagen, Venlo, Netherlands) and 10 ll of proteinase K solution (Promega, Madison, WI, USA) at 55°C overnight with the sample upside down. The day after samples were centrifuged for 10 min at 6,700 g and RNA extracted using the Maxwell â 16 LEV RNA FFPE Purification Kit (Promega) following manufacturer's instructions.
To prepare cDNA from RNA samples, the SMARTer Universal Low Input RNA kit (Clontech Laboratories) was employed following manufacturer's instructions. Libraries were prepared using the Ion TargetSeq Exome Enrichment kit, following the manufacturer's guidelines. Ion PI Sequencing 200 kit (Ion Torrent, Life Technologies). The Ion PI Chip (Ion Torrent) was prepared and calibrated for loading. The Ion PI Chip was loaded with a template-positive ISPs and run on the Ion Proton Sequencer.
Bioinformatic analysis
Bioinformatics analysis was carried out using several command line software included in Bio-Linux (http://nebc.nerc.ac.uk/tools/ bio-linux/bio-linux-7-info). Using Star aligner, the reads, previously filtered for quality and length, were processed and aligned to mouse genome (mm10 version). The unmapped reads, generated from the first step, were re-aligned by using Bowtie2. The reads mapped with Star and Bowtie2 were merged and processed with Cufflinks. Cufflinks uses the alignment file to assemble and reconstruct the transcriptome. Cuffdiff (included in Cufflinks) was used to calculate the differential gene expression between different groups (0, 4, 24, and 96 h). Cuffdiff calculates expression in two or more samples and tests the statistical significance of each observed change in expression between them. The statistical model used to evaluate changes assumes that the number of reads produced by each transcript is proportional to its abundance but fluctuates because of technical variability during library preparation and sequencing and because of biological variability between replicates of the same experiment (Trapnell et al, 2012) . RNA-seq data have been deposited in the ArrayExpress database at EMBL-EBI (www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-5730.
Droplet digital PCR
Droplet digital PCR (ddPCR) was carried out using the ddPCRTM Supermix for Probes (No dUTP), the QX200TM Droplet Generator, the QX200 Droplet Reader, the C1000 TouchTM Thermal Cycler, and the PX1TM PCR Plate Sealer (Bio-Rad, Hercules, CA, USA) following manufacturer's instructions. Reactions were performed in triplicate in a 96-well plate using 10 ll/reaction of 2× ddPCR Supermix for Probes (No dUTP), 1 ll/reaction of 20× target primers/probe (FAM or HEX, Bio-Rad), 1 ll/reaction of 20× reference primers/probe (FAM or HEX, Bio-Rad), 3 ll cDNA and 5 ll H 2 O. Detection of CXCL12 and GAPDH by ddPCR was performed using the following PrimePCR TM ddPCR TM Expression Probe Assay designed by Bio-Rad: CXCL12-FAM (ID: dMmuCPE511627, Bio-Rad) and GAPDH-HEX (ID: dMmuCPE5195283, Bio-Rad). All steps used a ramp rate of 2°C/s. Results were analyzed in the QX200 Droplet Reader, the RNA targets were quantified using the QuantaSoftTM Software (Bio-Rad), and results were expressed as fractional abundance.
NMJ immunohistochemistry
Anesthetized mice were locally injected close to LAL muscles with a-LTx as described above. Muscles were dissected at different time points and fixed in 4% PFA in PBS for 30 min at RT. Samples were quenched, permeabilized, and saturated for 2 h in 15% goat serum, 2% BSA, 0.25% gelatine, 0.20% glycine, and 0.5% Triton X-100 in PBS. Incubation with the primary antibodies was carried out for 72 h in blocking solution. Muscles were then washed and incubated with secondary antibodies.
Images were collected with a Leica SP5 Confocal microscope equipped with a 63× HCX PL APO NA 1.4. Laser excitation line, power intensity, and emission range were chosen accordingly to each fluorophore in different samples to minimize bleed-through.
RNA fluorescence in situ hybridization (FISH)
The Probe Designer tool was used to design a set of 48 oligonucleotide probes (Quasar â 570-conjugated) complementary to the Mus musculus CXCL12a transcript (NM_021704.3). Stellaris â RNA FISH buffers and probes were purchased by LGC Biosearch Technologies. In situ hybridization was performed on 7 to 10-lm-thick cryoslices according to the manufacturer's guidelines for frozen tissue. Images were collected as above.
Electrophysiological recordings
Electrophysiological recordings were performed in oxygenated Krebs-Ringer solution on soleus muscles using intracellular glass microelectrodes (WPI, Germany) filled with one part of 3 M KCl and two parts of 3 M CH 3 COOK. To determine the time course of NMJ degeneration and regeneration, anesthetized C57BL/6 female mice (2 months of age) were locally injected with the toxin in the hind limb (a-LTx 5 lg/kg), and soleus muscles were collected at 0, 4, 24, and 96 h from treatment. In another set of experiments recordings were performed on soleus muscles from mice i.p. injected with 100 lg of anti-CXCL12a antibody (diluted in 40 ll physiological solution plus 0.2% gelatine) prior to the local injection of a-LTx.
For experiments with the CXCR4 antagonist, mice were i.p. injected with 100 lg AMD3100 (in 40 ll physiological solution containing 0.2% gelatine) prior to local injection of a-LTx. AMD3100 administration was performed twice a day for 4 days.
To test the effect of chemokine administration on NMJ recovery, rCXCL12a was locally injected in soleus muscle (100 ng, 15 ll injection volume) 8, 24, and 48 h post-a-LTx injection. Electrophysiological recordings were performed after 72 h of intoxication.
Evoked neurotransmitter release was recorded in current-clamp mode, and resting membrane potential was adjusted with current injection to À70 mV. Evoked junction potentials (EJPs) were elicited by supramaximal nerve stimulation at 0.5 Hz using a suction microelectrode connected to a S88 stimulator (Grass, USA). To prevent muscle contraction after dissection, samples were incubated for 10 min with 1 lM l-Conotoxin GIIIB (Alomone, Israel). Signals were amplified with intracellular bridge mode amplifier (BA-01X, NPI, Germany), sampled using a digital interface (NI PCI-6221, 
Cell cultures and treatments
Primary cultures of SCMNs were prepared as described in Rigoni et al (2004) and exposed for 24 h to rCXCL12a (500 ng/ml, R&D) in culture medium. Low-density motor neuron cultures were used to test the effect of rCXCL12a on axon growth. In some experiments, AMD3100 (10 lM) was added to SCMNs together with rCXCL12a that was kept throughout the experiment. After 24 h, neurons were fixed and stained for b 3 -tubulin and axon growth quantified with the ImageJ plugin NeuronJ.
Microfluidic chambers
Microfluidic chambers were produced using established methods (Park et al, 2006) . Polydimethylsiloxane (Dow Corning) inserts were sterilized and fixed to 50-mm glass-bottomed WillCo dishes (IntraCel) using plasma cleaning. The chambers were blocked with 0.8% BSA in PBS overnight at 37°C and then coated with poly-L-ornithine and laminin. SCMNs were plated in the somatic compartment. rCXCL12a (500 ng/ml) was added to the distal compartment in the absence or presence of AMD3100 (added to the somatic chamber, 10 lM).
Neurons were allowed to grow for 5 days, fixed, and stained for b 3 -tubulin; axon growth was quantified with the ImageJ plugin NeuronJ.
Immunofluorescence
Cells were fixed for 15 min in 4% PFA in PBS, quenched (0.38% glycine, 0.24% NH 4 Cl in PBS), and permeabilized with 0.3% Triton X-100 in PBS for 5 min at room temperature. After saturation with 3% goat serum in PBS for 1 h, samples were incubated with primary antibodies (anti-b 3 -tubulin, 1:200; anti-CXCR4, 1:500; anti-GAP43, 1:200), diluted in 3% goat serum in PBS overnight at 4°C, washed, and then incubated with the corresponding secondary antibodies Alexa-conjugated for 1 h at room temperature. Coverslips were mounted in Mowiol and examined by confocal (Leica SP5) or epifluorescence (Leica CTR6000) microscopy.
Statistical analysis
Sample sizes were determined by analysis based on data collected by our laboratory in published studies. In animal studies, we used n = 6 mice/group for electrophysiological analysis. In cell culture studies, we performed each study with at least five independent replications. For all animal studies, we have ensured blinded conduct of experiments. For imaging analysis, the quantitation was conducted by an observer who was blind to the experimental groups. No samples or animals were excluded from the analysis. The sample size (N) of each experimental group is described in the corresponding figure legend. Data displayed as histograms are expressed as means AE SEM or SD (represented as error bars). GraphPad Prism software was used for all statistical analyses. Statistical significance was evaluated using analysis of variance (ANOVA) with Tukey post-test or two-tailed, unpaired Student's t-test depending on the number of groups to be analyzed. Data were considered statistically different when *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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The paper explained
Problem
The neuromuscular junction can regenerate after damage. Regeneration is driven by an intense signaling among the three main components of this synapse (motor axon terminal, perisynaptic Schwann cells, and muscle), but only few molecules governing this process have been identified so far.
Results
By combining a transcriptome analysis of murine NMJs during degeneration and regeneration with imaging and electrophysiological recordings, we provided strong evidence that the chemokine CXCL12a is released by a specialized type of glial cells termed perisynaptic Schwann cells and that it potently stimulates the functional recovery of the neuromuscular junction after an acute motor axon terminal degeneration. By interacting with the neuronal CXCR4 receptor, this chemokine promotes axonal elongation in primary spinal motor neurons.
Impact
These findings have high potential therapeutic value for the improvement of functional recovery of the neuromuscular junction after various types of insults, including genetic neurodegenerative syndromes, and in spinal cord diseases characterized by motor neuron loss.
